Helix BioMedix, Inc.

As of September 30, 2012, Helix BioMedix, Inc. carries a market capitalization of 11.43M, placing it among publicly traded companies globally. Its enterprise value stands at 11.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2012, Helix BioMedix, Inc. has 165,717.00 shares outstanding.

These figures are as of September 30, 2012. The price-to-sales ratio is 5.53, and the price-to-book ratio stands at 9.94.

These figures are as of September 30, 2012. The EV/Sales ratio of 5.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.22M versus a market cap of 11.43M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2012, Helix BioMedix, Inc. maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended September 30, 2012, Helix BioMedix, Inc. posted a negative return on equity (ROE) of -122.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -100.64, reflecting losses generated across the asset base. The company generates approximately 258,239.38 in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.87 indicates how many times Helix BioMedix, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 2, 2026, Helix BioMedix, Inc.'s stock has declined approximately 6.00% over the past 52 weeks. The 50-day moving average sits at 5.62, while the 200-day moving average is 28.39.

Over the twelve months ended September 30, 2012, Helix BioMedix, Inc. generated 2.07M in revenue and converted that into -2.58M in net income, yielding earnings per share of -15.59. EBITDA reached -2.33M, while operating income came in at -2.42M.

These figures are as of September 30, 2012. Total book value stands at 1.15M, with working capital of 690,402.00 providing operational flexibility.

Helix BioMedix, Inc. produced -1.82M in operating cash flow over the twelve months ended September 30, 2012. After subtracting 9,924.00 in capital expenditures, free cash flow totaled -1.81M - equivalent to -10.92 per share.

Over the twelve months ended September 30, 2012, Helix BioMedix, Inc. posted a gross margin of 68.96, reflecting its pricing power and cost economics. The operating margin of -117.30 and net profit margin of -125.06 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2012. Free cash flow yield is negative at -15.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Helix BioMedix, Inc. shareholders.

Helix BioMedix, Inc.'s most recent stock split took place on January 3, 2013 with a 300:1 split ratio.

As of September 30, 2012, Helix BioMedix, Inc. has an Altman Z-Score of -32.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.